American Society of Hematology

Figure 1.

Inhibition of ACVR1 by JAK inhibitors. (A) Strength of inhibition of ACVR1 by JAK2 inhibitors. The IC50 is shown in comparison with the Cmax achieved clinically. (B) Simulated free drug concentration for pacritinib and momelotinib relative to ACVR1 IC50. Data plotted as median concentration of free drug over time through steady state for pacritinib and for momelotinib (MMB) and its metabolite (M21).

Inhibition of ACVR1 by JAK inhibitors. (A) Strength of inhibition of ACVR1 by JAK2 inhibitors. The IC₅₀ is shown in comparison with the C_max achieved clinically. (B) Simulated free drug concentration for pacritinib and momelotinib relative to ACVR1 IC₅₀. Data plotted as median concentration of free drug over time through steady state for pacritinib and for momelotinib (MMB) and its metabolite (M21).

This Feature Is Available To Subscribers Only